心型脂肪酸结合蛋白联合超声心动图对脓毒症合并心功能不全的诊断价值
该前瞻性观察研究纳入2016年10月至2018年1月石河子大学医学院第一附属医院重症医学科收治的80例脓毒症患者,按心功能分为心功能正常组(n=30)和心功能不全组(n=50)。心功能不全组SOFA评分显著高于心功能正常组(6.12±4.09 vs. 4.57±2.45,P<0.05),N%和H-FABP在同时点均高于心功能正常组(N%:F=6.973,P=0.010;H-FABP:F=17.303,P=0.000)。ROC分析显示A'的AUC最高为0.908,H-FABP与各超声指标平行联合检测的阳性预测值均高于单一诊断试验,但阴性预测值降低。作者认为超声指标LVEDV、SV、LVEF、CO、LVFS、EPSS、IVRT、A'、Sm联合H-FABP对脓毒症相关心功能障碍的诊断有一定价值。
要点
- 心功能不全组SOFA评分显著高于心功能正常组(6.12±4.09 vs. 4.57±2.45,P<0.05),余一般资料两组比较无明显差异。
- 心功能不全组N%和H-FABP在同时点均高于心功能正常组(N%:F=6.973,P=0.010;H-FABP:F=17.303,P=0.000)。
- ROC分析中A'的诊断价值最高(AUC=0.908),其次为SV(AUC=0.779)、IVRT(AUC=0.775)、CO(AUC=0.754)、LVEF(AUC=0.753)、Sm(AUC=0.738)、LVFS(AUC=0.728)、H-FABP(AUC=0.673)、EPSS(AUC=0.663)、LVEDV(AUC=0.636)。
- H-FABP与LVEDV、SV、LVEF、CO、LVFS、EPSS、IVRT、A'、Sm平行联合检测的阳性预测值分别为85.45%、93.91%、96.72%、94.74%、89.43%、98.00%、92.00%、99.42%、93.60%,均高于单一诊断试验。
- 平行联合检测的阴性预测值分别为50.89%、57.93%、49.15%、58.18%、57.05%、45.74%、57.92%、64.13%、47.78%,均低于单一诊断试验。
适用人群与场景
- 2016年10月至2018年1月石河子大学医学院第一附属医院重症医学科收治的脓毒症患者80例,按心功能分为心功能正常组(n=30)和心功能不全组(n=50)。
研究设计与关键结果
- 研究类型为前瞻性观察性研究,纳入80例脓毒症患者,其中心功能正常组30例、心功能不全组50例。
- 心功能不全组SOFA评分显著高于心功能正常组(6.12±4.09 vs. 4.57±2.45,P<0.05),其余一般临床资料两组比较无明显差异。
- 心功能不全组N%和H-FABP在同时点均高于心功能正常组(N%:F=6.973,P=0.010;H-FABP:F=17.303,P=0.000)。
- 不考虑时间因素时,两组LVEDV、LVESV、LVEF、SV、CO、LVFS、EPSS、IVRT、EDT、Ad、S、D、E'、A'、Sm、PVBV差异有统计学意义。
- Logistic回归筛选出的超声指标及心肌标志物行ROC分析:LVEDV的AUC 0.636、阳性预测值77.30%、阴性预测值56.03%;SV的AUC 0.779、阳性预测值88.82%、阴性预测值71.19%;LVEF的AUC 0.753、阳性预测值92.12%、阴性预测值55.21%;CO的AUC 0.754、阳性预测值88.82%、阴性预测值77.19%;LVFS的AUC 0.728、阳性预测值81.25%、阴性预测值66.99%;EPSS的AUC 0.663、阳性预测值96.99%、阴性预测值51.56%;IVRT的AUC 0.775、阳性预测值86.97%、阴性预测值73.55%;A'的AUC 0.908、阳性预测值96.58%、阴性预测值89.60%;Sm的AUC 0.738、阳性预测值93.37%、阴性预测值56.77%;
- H-FABP与LVEDV、SV、LVEF、CO、LVFS、EPSS、IVRT、A'、Sm平行联合检测的阳性预测值分别为85.45%、93.91%、96.72%、94.74%、89.43%、98.00%、92.00%、99.42%、93.60%,均高于单一诊断试验;阴性预测值分别为50.89%、57.93%、49.15%、58.18%、57.05%、45.74%、57.92%、64.13%、47.78%,均低于单一诊断试验。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,心脏超声指标LVEDV、SV、LVEF、CO、LVFS、EPSS、IVRT、A'、Sm联合H-FABP对脓毒症相关心功能障碍的诊断有一定价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the value of heart-type fatty acid-binding protein (H-FABP) and echocardiographic indexes in the diagnosis of cardiac insufficiency in sepsis.
METHODS: A prospective observational study was conducted. Eighty patients with sepsis admitted to the department of critical care medicine of the First Affiliated Hospital of Medical College of Shihezi University from October 2016 to January 2018 were enrolled. General clinical data such as gender, age, acute physiology and chronic health evaluation II (APACHE II), sequential organ failure assessment (SOFA) score, hospitalization time and 28-day mortality were recorded. Echocardiographic indexes at 1, 3, 7, 10 days after diagnosis, and white blood cell (WBC), neutrophilic granulocyte percentage (N%), N-terminal pro-brain natriuretic peptide (NT-proBNP), serum H-FABP level were recorded. Sepsis patients were divided into normal cardiac function group (n = 30) and cardiac insufficiency group (n = 50) according to cardiac function, the differences of echocardiographic indexes and cardiac markers between the two groups at different time points were compared. Logistic regression was used to screen out cardiac ultrasound indexes and cardiac markers that affect the occurrence of cardiac dysfunction in sepsis patients, and then receiver operating characteristic (ROC) curve analysis was performed.
RESULTS: Comparing the general data of the two groups, only the SOFA score of the cardiac insufficiency group was significantly higher than that of the normal cardiac function group (6.12±4.09 vs. 4.57±2.45, P < 0.05). N% and H-FABP in cardiac insufficiency group were higher than those in normal cardiac function group at the same time (N%: F = 6.973, P = 0.010; H-FABP: F = 17.303, P = 0.000). Without considering the time factor, there were significant differences in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO), left ventricular fractional shortening (LVFS), E-point of septal separation (EPSS), isovolumic relaxation time (IVRT), E peak deceleration time (EDT), A peak duration (Ad), left ventricular systolic pulmonary vein velocity (S), blood flow velocity of pulmonary vein in early left ventricular diastolic period (D), tricuspid orifice early diastolic blood flow velocity (E'), tricuspid orifice late diastolic blood flow velocity (A'), systolic velocities of the right ventricular free wall tricuspid annulus (Sm), and pulmonary valve annulus blood flow velocity (PVBV) between the two groups. ROC curve analysis of cardiac ultrasound indicators and cardiac markers screened by Logistic regression showed that the area under ROC curve (AUC) and the positive and negative predictive values were: LVEDV was 0.636, 77.30%, 56.03%; SV was 0.779, 88.82%, 71.19%; LVEF was 0.753, 92.12%, 55.21%; CO was 0.754, 88.82%, 77.19%; LVFS was 0.728, 81.25%, 66.99%; EPSS was 0.663, 96.99%, 51.56%; IVRT was 0.775, 86.97%, 73.55%; A' was 0.908, 96.58%, 89.60%; Sm was 0.738, 93.37%, 56.77%; H-FABP was 0.673, 80.26%, 57.25%, respectively. H-FABP was tested in parallel with LVEDV, SV, LVEF, CO, LVFS, EPSS, IVRT, A', Sm, and the positive predictive values were higher than the single diagnostic test (85.45%, 93.91%, 96.72%, 94.74%, 89.43%, 98.00%, 92.00%, 99.42%, 93.60%, respectively), the negative predictive values were lower than the single diagnostic test (50.89%, 57.93%, 49.15%, 58.18%, 57.05%, 45.74%, 57.92%, 64.13%, 47.78%, respectively).
CONCLUSIONS: Cardiac ultrasound indicators LVEDV, SV, LVEF, CO, LVFS, EPSS, IVRT, A', and Sm combined with H-FABP are of certain value in the diagnosis of sepsis-associated heart dysfunction.
参考来源
- Ding R, Cheng Q, Tian P, et al. [Diagnostic value of heart-type fatty acid-binding protein combined with echocardiography in sepsis with cardiac insufficiency]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32527357. doi:10.3760/cma.j.cn121430-20191111-00064
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。